Burlingame, Feb. 06, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CAR T cell therapy market is estimated to be valued at US$ 2,259.5 million in 2022 and is expected to exhibit a CAGR of 20.9 % during the forecast period (2022-2030).
Key Trends and Analysis of the Global CAR T Cell Therapy Market:
Major players operating in the market are focusing on adopting strategies such as product approval, which is expected to drive the market growth over the forecast period. For instance, in September 2022, Legend Biotech, a commercial-stage biotechnology company developing and manufacturing novel therapies, announced the approval of CARVYKTI (ciltacabtagene autoleucel) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/102
Key Market Takeaways:
The global CAR T cell therapy market is expected to exhibit a CAGR of 20.9% during the forecast period due to increasing product approvals by regulatory bodies. For instance, in July 2020, Kite, a subsidiary of Gilead Company, received the U.S. Food and Drug Administration approval for Tecartus, a CAR-T cell therapy for treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Among Targeted Antigen, CD19 is expected to hold a dominant position over the forecast period, owing to promising results of therapy. For instance, in June 2022, American Society of Hematology published a data according to which CD19 CAR T cell therapy is used as novel cell therapy which shows promising results in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Among region, North America segment is expected to hold a dominant position over the forecast period, owing to increase in research and development activities by research institutes. For instance, in August 2022, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, research center for pediatric cancers and blood diseases has developed a new technique in which generic CAR T cells are prepared by using induced pluripotent stem cells (iPS cells) and could be produced at scale for use in multiple patients.
Competitive Landscape:
Key players operating in the global CAR T cell therapy market include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/102
Market Segmentation:
- Global CAR T Cell Therapy Market, By Targeted Antigen:
- CD19
- BCMA
- HER2
- GD2
- CD20
- CD22
- CD30
- CD33
- HER1
- Others (CLDN18, etc.)
- Global CAR T Cell Therapy Market, By Therapeutic Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others (Gastric Cancer, etc.)
- Global CAR T Cell Therapy Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Bovine Plasma Market, by Grade (Technical and Standard), by Origin (U.S., Australia, New Zealand, and Others (Brazil, Mexico, etc.)), by Application (Cell Culture Media, Vaccine Production, Drug Discovery, and Others (Forensic Studies, in vitro diagnostics, etc.)), by End User (Biopharmaceutical Industry, Academic & Research Institutes, and Others (Diagnostic Laboratories, Forensic Laboratories, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
